Free tool
FAERS Monitor: Tri-Luma
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021112 or its brand name (Tri-Luma, Fluocinolone Acetonide, Hydroquinone, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
548
Serious
47
9% of reports
Hospitalization
15
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- erythema161
- drug ineffective123
- skin burning sensation91
- condition aggravated73
- skin exfoliation69
- product use issue54
- dry skin52
- pruritus51
- skin irritation51
- intentional product use issue50
- intentional product misuse48
- skin hyperpigmentation48
- drug ineffective for unapproved indication43
- incorrect product storage43
- product use in unapproved indication39
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 91 |
| 2016 | 86 |
| 2017 | 110 |
| 2018 | 22 |
| 2019 | 48 |
| 2020 | 47 |
| 2021 | 4 |
| 2022 | 18 |
| 2023 | 19 |
| 2024 | 15 |
| 2025 | 19 |
| 2026 | 25 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,611 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin hyperpigmentationSignal | 48 | 215.6 | 164.4 | 9,987 |
| incorrect product storageSignal | 43 | 126.0 | 94.5 | 5,194 |
| skin burning sensationSignal | 91 | 48.8 | 40.5 | 4,223 |
| skin irritationSignal | 51 | 42.8 | 32.9 | 2,041 |
| skin exfoliationSignal | 69 | 31.4 | 25.2 | 2,008 |
| drug ineffective for unapproved indicationSignal | 43 | 30.1 | 22.6 | 1,183 |
| erythemaSignal | 161 | 30.1 | 26.4 | 4,539 |
| intentional product use issueSignal | 50 | 21.9 | 16.8 | 981 |
| intentional product misuseSignal | 48 | 21.1 | 16.1 | 900 |
| dry skinSignal | 52 | 15.0 | 11.5 | 667 |
| product use issueSignal | 54 | 11.0 | 8.6 | 487 |
| condition aggravatedSignal | 73 | 9.2 | 7.4 | 534 |
| product use in unapproved indicationSignal | 39 | 6.0 | 4.5 | 161 |
| pruritusSignal | 51 | 5.1 | 3.9 | 167 |
| drug ineffectiveSignal | 123 | 3.6 | 3.1 | 241 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.